CY1113665T1 - Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη - Google Patents

Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη

Info

Publication number
CY1113665T1
CY1113665T1 CY20121101227T CY121101227T CY1113665T1 CY 1113665 T1 CY1113665 T1 CY 1113665T1 CY 20121101227 T CY20121101227 T CY 20121101227T CY 121101227 T CY121101227 T CY 121101227T CY 1113665 T1 CY1113665 T1 CY 1113665T1
Authority
CY
Cyprus
Prior art keywords
receptor
positive allosteric
benzokinazolinone
arylmethyl
compounds
Prior art date
Application number
CY20121101227T
Other languages
English (en)
Inventor
Scott D Kuduk
Douglas C Beshore
Marco Christina Ng Di
Thomas J Greshock
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1113665T1 publication Critical patent/CY1113665T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/19—Acids containing three or more carbon atoms
    • C07C53/21—Acids containing three or more carbon atoms containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Η παρούσα εφεύρεση στρέφεται προς ενώσεις βενζο-κιναζολίνης του χημικού τύπου (I) οι οποίες είναι θετικοί αλλοστερικοί ρυθμιστές του υποδοχέα Μ1 και οι οποίοι χρησιμεύουν στην αγωγή ενώσεων στους οποίους συμμετέχει ο υποδοχέας Μ1, όπως νόσο του Αλτσχάιμερ, σχιζοφρένεια, διαταραχές του πόνου ή του ύπνου. Επίσης, η εφεύρεση στρέφεται σε φαρμακευτικά σκευάσματα που περιέχουν αυτές τις ενώσεις και την χρήση των ενώσεων και των συνθέσεων στην αγωγή νοσημάτων που διαμεσολαβούνται από τον υποδοχέα Μ1.
CY20121101227T 2008-11-20 2012-12-17 Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη CY1113665T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19974008P 2008-11-20 2008-11-20
EP09761104A EP2358686B1 (en) 2008-11-20 2009-11-19 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
CY1113665T1 true CY1113665T1 (el) 2016-06-22

Family

ID=41565956

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101227T CY1113665T1 (el) 2008-11-20 2012-12-17 Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη

Country Status (37)

Country Link
US (4) US8557832B2 (el)
EP (1) EP2358686B1 (el)
JP (1) JP5102397B2 (el)
KR (1) KR101305590B1 (el)
CN (1) CN102292323B (el)
BR (1) BRPI0921924A2 (el)
CA (1) CA2743562C (el)
CO (1) CO6361928A2 (el)
CR (1) CR20110268A (el)
CY (1) CY1113665T1 (el)
DK (1) DK2358686T3 (el)
DO (1) DOP2011000135A (el)
EA (1) EA019098B1 (el)
EC (1) ECSP11011066A (el)
ES (1) ES2393694T3 (el)
GE (1) GEP20156348B (el)
GT (1) GT201100127A (el)
HK (1) HK1154587A1 (el)
HN (1) HN2011001358A (el)
HR (1) HRP20120992T1 (el)
IL (1) IL212573A (el)
MA (1) MA32898B1 (el)
MX (1) MX2011005284A (el)
MY (1) MY162502A (el)
NI (1) NI201100100A (el)
NZ (1) NZ592961A (el)
PE (1) PE20120031A1 (el)
PL (1) PL2358686T3 (el)
PT (1) PT2358686E (el)
RS (1) RS52528B (el)
SG (1) SG171769A1 (el)
SI (1) SI2358686T1 (el)
SV (1) SV2011003912A (el)
TN (1) TN2011000209A1 (el)
UA (1) UA100459C2 (el)
WO (1) WO2010059773A1 (el)
ZA (1) ZA201103612B (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2473048T3 (pl) * 2009-08-31 2015-08-31 Merck Sharp & Dohme Pozytywne modulatory allosteryczne receptora M1 piranyloarylometylobenzochinazolinonowe
US8895580B2 (en) 2009-10-21 2014-11-25 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone M1 receptor positive allosteric modulators
US8664387B2 (en) * 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
MA33920B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
WO2011084371A1 (en) * 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
EP2582241B1 (en) 2010-06-15 2016-04-06 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
EP2588104B1 (en) 2010-07-01 2014-12-10 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2012047702A1 (en) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
WO2012158473A1 (en) 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
EA201400215A1 (ru) 2011-08-12 2014-07-30 Басф Се Антраниламидные соединения и их применение в качестве пестицидов
IN2014CN00981A (el) 2011-08-12 2015-04-10 Basf Se
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013105117A1 (en) * 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research Cu-MEDIATED ANNULATION FOR THE PRODUCTION OF 1-AMINO-2-NAPHTHALENECARBOXYLIC ACID DERIVATIVES
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
JP6211530B2 (ja) 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6540690B2 (ja) * 2014-04-17 2019-07-10 住友化学株式会社 ニトロ化合物の製造方法
US20180050018A1 (en) * 2015-03-06 2018-02-22 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
EA201890152A1 (ru) 2015-06-26 2018-08-31 Такеда Фармасьютикал Компани Лимитед Производные 2,3-дигидро-4h-1,3-бензоксазин-4-онов в качестве модуляторов холинергического мускаринового m1 рецептора
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
EP3356332A4 (en) 2015-09-30 2019-06-19 Merck Sharp & Dohme Corp. METHOD FOR PRODUCING POSITIVE ALLOSTERIC M1 RECEPTOR MODULATORS
EP3356333A4 (en) * 2015-09-30 2019-03-27 Merck Sharp & Dohme Corp. CRYSTAL FORMS OF AN M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR
EP3366679B1 (en) * 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3442972T3 (da) 2016-04-15 2020-04-27 Abbvie Inc Bromdomænehæmmere
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AU2017342205A1 (en) * 2016-10-14 2019-04-04 Pi Industries Ltd 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
EP3535253A1 (en) 2016-11-01 2019-09-11 H. Hoffnabb-La Roche Ag 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of cns related diseases
US20200182850A1 (en) 2017-05-19 2020-06-11 Takeda Pharmaceutical Company Limited Screening method
US20210347786A1 (en) 2018-09-28 2021-11-11 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20240092783A1 (en) 2021-03-18 2024-03-21 Merck Patent Gmbh Heteroaromatic compounds for organic electroluminescent devices
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT856001E (pt) * 1995-10-02 2003-01-31 Hoffmann La Roche Derivados de pirimidina enquanto antagonistas do receptor 5ht2c
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
ES2244243T3 (es) * 1998-10-16 2005-12-01 Sumitomo Pharmaceuticals Company, Limited Deerivados de quinazolinona.
JP2005089298A (ja) * 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
US20060233843A1 (en) 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
EP1888538B1 (en) * 2005-05-04 2009-11-18 F. Hoffmann-Roche AG (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-ht receptor
ATE530544T1 (de) * 2006-06-28 2011-11-15 Merck Sharp & Dohme Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
WO2012047702A1 (en) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
US8883810B2 (en) 2014-11-11
EP2358686B1 (en) 2012-09-26
ECSP11011066A (es) 2011-06-30
DK2358686T3 (da) 2013-01-07
EA019098B1 (ru) 2014-01-30
HRP20120992T1 (hr) 2012-12-31
HN2011001358A (es) 2014-03-03
PE20120031A1 (es) 2012-02-05
SG171769A1 (en) 2011-07-28
MX2011005284A (es) 2011-06-17
US20150031713A1 (en) 2015-01-29
CA2743562A1 (en) 2010-05-27
ZA201103612B (en) 2012-01-25
JP2012509343A (ja) 2012-04-19
DOP2011000135A (es) 2011-07-31
CN102292323A (zh) 2011-12-21
GEP20156348B (en) 2015-08-25
IL212573A (en) 2015-01-29
NI201100100A (es) 2011-09-12
NZ592961A (en) 2012-09-28
KR101305590B1 (ko) 2013-09-09
US8557832B2 (en) 2013-10-15
KR20110073596A (ko) 2011-06-29
PT2358686E (pt) 2012-12-06
HK1154587A1 (en) 2012-04-27
RS52528B (en) 2013-04-30
SV2011003912A (es) 2011-10-13
BRPI0921924A2 (pt) 2015-12-29
US20110224198A1 (en) 2011-09-15
UA100459C2 (en) 2012-12-25
EA201170705A1 (ru) 2011-12-30
MA32898B1 (fr) 2011-12-01
TN2011000209A1 (en) 2012-12-17
MY162502A (en) 2017-06-15
CN102292323B (zh) 2014-12-24
CO6361928A2 (es) 2012-01-20
US20160229813A1 (en) 2016-08-11
WO2010059773A1 (en) 2010-05-27
AU2009316578A1 (en) 2011-06-23
CA2743562C (en) 2014-03-18
IL212573A0 (en) 2011-06-30
EP2358686A1 (en) 2011-08-24
PL2358686T3 (pl) 2013-02-28
US20140005182A1 (en) 2014-01-02
US9708273B2 (en) 2017-07-18
CR20110268A (es) 2011-07-01
ES2393694T3 (es) 2012-12-27
JP5102397B2 (ja) 2012-12-19
SI2358686T1 (sl) 2013-05-31
GT201100127A (es) 2014-02-10

Similar Documents

Publication Publication Date Title
CY1113665T1 (el) Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη
CY1117726T1 (el) Θετικοι αλλοστερικοι ρυθμιστες υποδοχεα μ1 κινολιναμιδιου
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1115318T1 (el) Ισοκινολινο ρυθμιστες μεταφορεων κασετας συνδεσης ατρ
CY1114277T1 (el) ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
PA8842101A1 (es) Heteroarilos sustituidos
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CY1115836T1 (el) Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
DE602006015851D1 (de) Positive allosterische chinolon-m1-rezeptormodulatoren
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CY1117705T1 (el) Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CY1113743T1 (el) Παραγωγα ισοκινολινονης ως ανταγωνιστες toy νκ3